Skip to content

Serum or Plasma Free Light Chain Immunoglobulin Quantification (Quantitative Free Light Chains)

Published: August 9, 2026Updated: August 16, 2026

This test measures the levels of free light chains, which are small protein fragments produced when antibodies break down. It helps assess conditions affecting antibody production or immune system function.

Quick summary

["Free light chains can signal underlying immune disorders or kidney issues."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
58909-3
Short code
11DC 20M p chal SerPl-mCnc
Synonyms
11DC 20M p chal SerPl-mCnc
Category
hormone
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

Why This Test Is Done

Your doctor may order this test to investigate symptoms like fatigue, weight changes, or unexplained kidney problems. It’s also used to monitor conditions like multiple myeloma, lymphoma, or other immune-related diseases where antibody levels are abnormal.

What to Expect Before the Test

No special preparation is needed. You’ll provide a blood sample, either serum (blood processed without clotting) or plasma (blood with clotting factors removed). The test is typically done in a lab from a small blood draw.

What the Results Mean

Results show the concentration of free light chains in your blood. Elevated levels may indicate conditions like multiple myeloma, where abnormal antibody production occurs, or kidney disease affecting protein filtering.

Common Conditions Monitored

This test helps diagnose or track conditions like multiple myeloma, Waldenström macroglobulinemia, or other monoclonal gammopathies. It may also be used in kidney disease evaluation if protein abnormalities are suspected.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Clinical Significance: Free light chains are fragments of heavy and light chains of immunoglobulins (antibodies). When antibodies break down, these light chains can accumulate in the blood or kidneys. Elevated levels often point to monoclonal gammopathies (e.g., multiple myeloma) or kidney dysfunction, guiding treatment decisions or disease management.

Short name

Free Light Chains

Frequently asked questions

What causes abnormal free light chain levels?
Abnormal levels are most commonly linked to diseases like multiple myeloma, where abnormal plasma cells produce excessive light chains. Kidney disease, infections, or certain autoimmune conditions may also affect these levels.
How often should I get this test?
Your doctor will determine frequency based on your health condition. For example, patients with multiple myeloma may need monitoring every few months, while others may only need it once.
Can diet or medications affect this test?
Dietary changes or most over-the-counter medications typically do not interfere. However, certain medications (e.g., chemotherapy for cancer) or kidney disease treatments may indirectly influence results. Always discuss with your doctor.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy